Page 1 | Search Results | Blood | American Society of Hematology

1-13 of 13

Sort by

Sort Order Select

Journal Articles

Thrombocytosis and leukocytosis interaction in vascular complications of essential thrombocythemia

Alessandra Carobbio, Guido Finazzi, Elisabetta Antonioli, Paola Guglielmelli, Alessandro M. Vannucchi, Federica Delaini, Vittoria Guerini, Marco Ruggeri, Francesco Rodeghiero, Alessandro Rambaldi, Tiziano Barbui

Blood (2008) 112 (8): 3135–3137.

https://doi.org/10.1182/blood-2008-04-153783

Published: 2008

Journal Articles

Characteristics and clinical correlates of MPL 515W>L/K mutation in essential thrombocythemia

Blood (2008) 112 (3): 844–847.

https://doi.org/10.1182/blood-2008-01-135897

Published: 2008

Includes: Supplemental data

Journal Articles

Selective Targeting of the JAK2 V617F Mutation in Polycythemia Vera and Essential Thrombocythemia by ITF2357, a Novel Histone Deacetylase Inhibitor.

Vittoria Guerini, PhD, Valentina Barbui, PhD, Orietta Spinelli, PhD, Anna Salvi, Chiara Dellacasa, MD, Martino Introna, MD, Tiziano Barbui, MD, Josée Golay, PhD, Alessandro Rambaldi, MD

Blood (2007) 110 (11): 555.

https://doi.org/10.1182/blood.V110.11.555.555

Published: 2007

Journal Articles

Minimal Residual Disease (MRD)-Oriented Therapy of Adult Acute Lymphoblastic Leukemia (ALL): Final Results of Northern Italy Leukemia Group Study 09/00.

Renato Bassan, MD, Orietta Spinelli, BSc, Elena Oldani, BSc, Tamara Intermesoli, MD, Manuela Tosi, BSc, Barbara Peruta, BSc, Vittoria Guerini, BSc, Giuseppe Rossi, MD, Enrico Pogliani, MD, Eros Di Bona, MD, Pietro Fabris, MD, Agostino Cortelezzi, MD, Teodoro Chisesi, MD, Emanuele Angelucci, MD, Franco Leoni, MD, Fabio Ciceri, MD, Daniele Mattei, MD, Tiziano Barbui, MD, Alessandro Rambaldi, MD

Blood (2007) 110 (11): 3497.

https://doi.org/10.1182/blood.V110.11.3497.3497

Published: 2007

Journal Articles

The Clinical Phenotype of Patients with Essential Thrombocythemia Harboring MPL 515W>L/K Mutation.

Alessandro M. Vannucchi, MD, Elisabetta Antonioli, MD, Alessandro Pancrazzi, BiSc, Paola Guglielmelli, MD, Simonetta Di Lollo, MD, Renato Alterini, MD, Vittoria Guerini, BiSc, Gianna Baroni, BiSc, Alessandro Rambaldi, MD, Alberto Bosi, MD, Tiziano Barbui, MD

Blood (2007) 110 (11): 678.

https://doi.org/10.1182/blood.V110.11.678.678

Published: 2007

Journal Articles

Leukocytosis and Risk Stratification Assessment in Essential Thrombocythemia.

Alessandra Carobbio, Elisabetta Antonioli, Alessandro M. Vannucchi, Federica Delaini, Vittoria Guerini, Guido Finazzi, Alessandro Rambaldi, Tiziano Barbui

Blood (2007) 110 (11): 681.

https://doi.org/10.1182/blood.V110.11.681.681

Published: 2007

Journal Articles

Clinical profile of homozygous JAK2 617V>F mutation in patients with polycythemia vera or essential thrombocythemia

Blood (2007) 110 (3): 840–846.

https://doi.org/10.1182/blood-2006-12-064287

Published: 2007

Includes: Supplemental data

Journal Articles

Leukocytosis is a risk factor for thrombosis in essential thrombocythemia: interaction with treatment, standard risk factors, and Jak2 mutation status

Alessandra Carobbio, Guido Finazzi, Vittoria Guerini, Orietta Spinelli, Federica Delaini, Roberto Marchioli, Giovanna Borrelli, Alessandro Rambaldi, Tiziano Barbui

Blood (2006) 109 (6): 2310–2313.

https://doi.org/10.1182/blood-2006-09-046342

Published: 2006

Journal Articles

Potent Inhibition of EEC Colony Formation in JAK2 V617F PV and ET by Low Doses of ITF2357, a New Histone Deacetylase Inhibitor.

Vittoria Guerini, PhD, Orietta Spinelli, Biol Sc, Anna Salvi, Guido Finazzi, MD, Tiziano Barbui, MD, Martino Introna, MD, Josee Golay, Biol Sc, Alessandro Rambaldi, MD

Blood (2006) 108 (11): 2702.

https://doi.org/10.1182/blood.V108.11.2702.2702

Published: 2006

Journal Articles

Distinct Hemostatic Profile of Leukocytes in Essential Thrombocythemia (ET) Carrying the JAK2 V617F Mutation.

Anna Falanga, MD, Marina Marchetti, BSc, PhD, Donatella Balducci, BSc, Alfonso Vignoli, BSc, Laura Russo, BSc, Vittoria Guerini, BSc, Alessandro Rambaldi, MD, Tiziano Barbui, MD

Blood (2005) 106 (11): 378.

https://doi.org/10.1182/blood.V106.11.378.378

Published: 2005

Journal Articles

Risk-Adapted Therapy of Adult Acute Myeloid Leukemia (AML): Safety and Efficacy of Repetitive HD-ARA-C Courses with Low-Dose Autologous Blood Stem Cell Support.

Tamara Intermesoli, MD, Elena Oldani, Biol.Sci., Caterina Micò, MD, Vittoria Guerini, Biol.Sci., Anna Salvi, Emanuela Ruggeri, Andrea Rossi, MD, Ursula Giussani, Biol.Sci., Piero Bellavita, MD, Alessandro Rambaldi, MD, Tiziano Barbui, MD, Renato Bassan, MD

Blood (2005) 106 (11): 2934.

https://doi.org/10.1182/blood.V106.11.2934.2934

Published: 2005

Journal Articles

JAK2 Val617Phe Mutation Correlates with the Risk of Thrombosis in Patients with Essential Thrombocythemia.

Guido Finazzi, MD, Vittoria Guerini, Biol.Sci., Alessandro Rambaldi, MD, Tiziano Barbui, MD

Blood (2005) 106 (11): 2580.

https://doi.org/10.1182/blood.V106.11.2580.2580

Published: 2005

Journal Articles

Low Prevalence of JAK2 Val617Phe Mutation in Patients with Idiopathic Erythrocytosis.

Guido Finazzi, MD, Vittoria Guerini, Biol.Sci., Marco Ruggeri, MD, Martina Bernardi, Biol.Sci., Alessandro Rambaldi, MD, Francesco Rodeghiero, MD, Tiziano Barbui, MD

Blood (2005) 106 (11): 2581.

https://doi.org/10.1182/blood.V106.11.2581.2581

Published: 2005

NARROW

Thrombocytosis and leukocytosis interaction in vascular complications of essential thrombocythemia

Characteristics and clinical correlates of MPL 515W>L/K mutation in essential thrombocythemia

Selective Targeting of the JAK2 V617F Mutation in Polycythemia Vera and Essential Thrombocythemia by ITF2357, a Novel Histone Deacetylase Inhibitor.

Minimal Residual Disease (MRD)-Oriented Therapy of Adult Acute Lymphoblastic Leukemia (ALL): Final Results of Northern Italy Leukemia Group Study 09/00.

The Clinical Phenotype of Patients with Essential Thrombocythemia Harboring MPL 515W>L/K Mutation.

Leukocytosis and Risk Stratification Assessment in Essential Thrombocythemia.

Clinical profile of homozygous JAK2 617V>F mutation in patients with polycythemia vera or essential thrombocythemia

Leukocytosis is a risk factor for thrombosis in essential thrombocythemia: interaction with treatment, standard risk factors, and Jak2 mutation status

Potent Inhibition of EEC Colony Formation in JAK2 V617F PV and ET by Low Doses of ITF2357, a New Histone Deacetylase Inhibitor.

Distinct Hemostatic Profile of Leukocytes in Essential Thrombocythemia (ET) Carrying the JAK2 V617F Mutation.

Risk-Adapted Therapy of Adult Acute Myeloid Leukemia (AML): Safety and Efficacy of Repetitive HD-ARA-C Courses with Low-Dose Autologous Blood Stem Cell Support.

JAK2 Val617Phe Mutation Correlates with the Risk of Thrombosis in Patients with Essential Thrombocythemia.

Low Prevalence of JAK2 Val617Phe Mutation in Patients with Idiopathic Erythrocytosis.

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only